Navigation Links
BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results
Date:2/26/2008


Conference Call and Webcast to Be Held Today at 5:00 p.m. ET (22:00 CET)

2007 Financial Highlights

- Total BioMarin revenue of $121.6 million

- Naglazyme net product revenue of $86.2 million, an increase of 85.4

percent over 2006 and above BioMarin's guidance range of $82 million

to $84 million

- Aldurazyme net product revenue of $123.7 million, an increase of 28.5

percent over 2006 and toward the upper end of BioMarin's guidance

range of $115 million to $125 million

- Net loss of $15.8 million, within the guidance range of a loss of $13

million to $18 million

- Net income of $2.6 million in the fourth quarter of 2007

2008 Financial Guidance

- Total BioMarin revenue in the range of $255 million to $306 million

which includes total product revenue of $213 million to $264 million

- Naglazyme net product revenue in the range of $105 million to $116

million

- Aldurazyme net product sales by Genzyme of $135 million to $145

million with net revenue to BioMarin from royalties and transfers of

inventory in the range of $68 million to $78 million

- Improved Kuvan net product revenue guidance in the range of $40

million to $70 million

- GAAP net income in the range of $20 million to $40 million and

non-GAAP net income in the range of $47 million to $67 million

NOVATO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced financial results for the fourth quarter and full year ended December 31, 2007. Net income was $2.6 million ($0.03 per share) for the fourth quarter of 2007, compared to a net loss of $10.4 million ($0.11 per share) for the fourth quarter of 2006. Net income for the fourth quarter of 2007 includes the receipt of the $15.0 million milestone payment from Merck Serono related tostock-based compensation

expense $3,091 $5,465 $9,590 $18,283

BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

December 31, 2006 and 2007

(In thousands, except for share and per share data)

December 31, December 31,

2006 2007

ASSETS

Current assets:

Cash and cash equivalents $89,162 $228,343

Short-term investments 199,685 357,251

Accounts receivable, net 14,670 16,976

Advances to BioMarin/Genzyme LLC 1,596 2,087

Inventory 25,075 32,445

Other current assets 4,036 7,195

Total current assets 334,224 644,297

Investment in BioMarin/Genzyme LLC 31,457 44,881

Property, plant and equipment, net 55,466 76,818

Intangible assets, net 11,655 9,596

Goodwill 21,262 21,262

Restricted cash 1,731 2,889

Other assets 7,641 15,536

Total assets $463,436 $815,279

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities $32,166 $49,907

Current portion of acquisition obligation,

net of discount 6,787 6,309

Current portion of deferred revenue 7,092 5,327

Total current liabilities 46,045 61,543

Convertible debt 223,940 497,375

Long-term portion of acquisition obligation,

net of discount 68,548 66,553

Deferred revenue, net of current portion 5,023 --

Other long-term liabilities 2,078 2,082

Total liabilities 345,634 627,553

Stockholders' equity:

Common stock, $0.001 par value:

150,000,000 and 250,000,000 shares

authorized at December 31, 2006 and

December 31, 2007, respectively;

91,725,528 and 97,114,159 shares

issued and outstanding at December

31, 2006 and December 31, 2007,

respectively 92 97

Additional paid-in capital 709,359 794,917

Accumulated other comprehensive loss (25) 139

Accumulated deficit (591,624) (607,427)

Total stockholders' equity 117,802 187,726

Total liabilities and stockholders'

equity $463,436 $815,279

the EMEA acceptance of the Kuvan filing for marketing approval. The net loss for the year ended December 31, 2007 was $15.8 million ($0.16 per share), compared to a net loss of $28.5 million ($0.34 per share) for the year ended December 31, 2006. Non-cash stock compensation expense for the three months and year ended December 31, 2007 was $5.5 million and $18.3 million, respectively, compared to $3.1 million and $9.6 million, respectively, for the three months and year ended December 31, 2006.

As of December 31, 2007, BioMarin had cash, cash equivalents, and short-term investments totaling $585.6 million.

"We achieved many significant milestones in 2007, most notably, the FDA approval of Kuvan and the filing of the IND for PEG-PAL for PKU," said Jean-Jacques Bienaime, Chief Executive Officer of BioMarin. "We also continued building our pipeline with the in-licensing of promising compounds. As we look forward in 2008, we are focused on ensuring the successful commercial launch of Kuvan, further advancement of our research programs, and new in-licensing opportunities. Overall, we expect continued global expansion of Naglazyme and the U.S. launch of Kuvan to contribute to the improvement of our bottom line."

Product Revenue

Net revenue from Naglazyme(R) (galsulfase), an enzyme replacement therapy for mucopolysaccharidosis VI (MPS VI), was $25.5 million for the fourth quarter of 2007, an increase of 56.4 percent compared to net revenue of $16.3 million for the fourth quarter of 2006. Net revenue from Naglazyme for the year ended December 31, 2007 was $86.2 million, an increase of 85.4 percent from net revenue of $46.5 million for the year ended December 31, 2006. BioMarin is commercializing Naglazyme in the United States, Europe, and Latin America, and through distributors in other international markets.

Net revenue from Aldurazyme(R) (laronidase), an enzyme replacement therapy for mucopolysaccharidosis I, (MPS I) recorded by BioMarin/Genzyme LLC increased by approximately 33.6 percent to $35.4 million for the fourth quarter of 2007, compared to $26.5 million in the fourth quarter of 2006. Net revenue from Aldurazyme for the year ended December 31, 2007 was $123.7 million, an increase of 28.5 percent compared to net revenue of $96.3 million for the year ended December 31, 2006. BioMarin's share of the profit of BioMarin/Genzyme LLC was $9.4 million for the fourth quarter of 2007, compared to a profit of $5.7 million for the fourth quarter of 2006. For the year ended December 31, 2007, BioMarin's share of the profit of BioMarin/Genzyme LLC was $30.5 million, compared to a profit of $19.3 million for the year ended December 31, 2006. Beginning January 1, 2008, as a result of the restructuring of the joint venture with Genzyme, BioMarin will receive 39.5 to 50 percent of worldwide net sales of Aldurazyme as product revenue and will also recognize additional product revenue related to the transfer of Aldurazyme inventory to Genzyme to meet future product demand.

Net product revenue from Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), for the approximate two-week period after approval and launch in December 2007 was $0.4 million, which reflects initial shipments to a limited number of specialty pharmacies.

Collaborative Agreement Revenues

Collaborative agreement revenues for the fourth quarter of 2007 were $17.5 million, and include the $15 million milestone payment from Merck Serono for the filing of the MAA for Kuvan. Collaborative agreement revenues for the fourth quarter of 2006 were $4.9 million. Collaborative agreement revenues for the year ended December 31, 2007 were $28.3 million, compared to revenues of $18.7 million for the year ended December 31, 2006. Excluding the receipt of the $15 million milestone payment, collaborative agreement revenues decreased in 2007 as compared to 2006. This was due to decreased Kuvan research and development expenses reimbursable by Merck Serono resulting in decreased reimbursement revenue.

2008 Financial Guidance

BioMarin estimates 2008 net sales of Naglazyme will be in the range of $105 million to $116 million. BioMarin is updating its 2008 Kuvan net sales estimate to a range of $40 million to $70 million.

Net sales of Aldurazyme by Genzyme are estimated to be in the range of $135 million to $145 million. BioMarin's revenue from Genzyme related to Aldurazyme is estimated to be between $68 million and $78 million, which includes both the royalty earned on net sales by Genzyme and additional product revenue related to the transfer of Aldurazyme inventory to Genzyme to meet future product demand. This guidance reflects the new arrangement with Genzyme and the related changes in BioMarin's income statement presentation of Aldurazyme operations resulting from the restructuring of BioMarin/Genzyme LLC.

BioMarin estimates its Generally Accepted Accounting Principles (GAAP) net income for the fiscal year ending December 31, 2008 will be in the range of $20 million to $40 million which assumes that the $30 million milestone for EU Kuvan approval will be earned in 2008. The net income estimate includes approximately $27 million in non-cash stock compensation expense. Non-GAAP net income, excluding the impact of non-cash stock compensation, is estimated to be in the range of $47 million to $67 million.

Non-GAAP Financial Information and Reconciliation

The above 2008 financial guidance includes Management's estimated net income determined in accordance with GAAP and non-GAAP net income, which is net income calculated in accordance with GAAP, but excluding Management's estimate of non-cash stock compensation expense for 2008 of $27.0 million, a non-GAAP financial measure. The reconciliation of this measure to the estimated GAAP net income is as follows:

GAAP estimated net income for 2008 $20 - $40 million

Add estimated non-cash stock compensation $27.0 million

Non-GAAP estimated net income for 2008 $47 - $67 million

Management believes that this non-GAAP information is useful to investors, taken in conjunction with BioMarin's GAAP net income guidance for 2008 because Management uses such information internally for its operating, budgeting and financial planning purposes, and to enhance investors' overall understanding of the company's prospects for the future.

Anticipated Upcoming Milestones

-- 1Q08/early 2Q08: Initiation of PEG-PAL Phase I patient study with

plans to roll into a Phase 2 study in 3Q08

-- 4Q08: Results from Phase 2 Sickle Cell Disease trial

-- 4Q08: Results from Phase 2 PAD trial

Upcoming Investor Conferences and Events

-- March 17-19: Citi Small/Mid Cap Conference -- Las Vegas

-- March 17-20: Cowen Healthcare Conference -- Boston

-- March 18-20: Lehman Brothers Global Healthcare Conference -- Miami

-- June 5: BioMarin R&D Day -- New York City

BioMarin will host a conference call and webcast to discuss fourth quarter and full year 2007 financial results today, Tuesday, February 26, at 5:00 p.m. ET (22:00 CET). This event can be accessed on the investor section of the BioMarin website at http://www.BMRN.com.

Date: February 26, 2008

Time: 5:00 p.m. ET (22:00 CET)

U.S. / Canada Dial-in Number: 866.713.8564

International Dial-in Number: 617.597.5312

Participant Code: 79434433

Replay Dial-in Number: 888.286.8010

Replay International Dial-in Number: 617.801.6888

Replay Code: 87203261

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(TM) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU. For additional information, please visit http://www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of revenue and sales related to Naglazyme, Kuvan, and Aldurazyme; the financial performance of the BioMarin as a whole; the timing of BioMarin's clinical trials of 6R-BH4 for other indications and PEG-PAL; the continued clinical development and commercialization of Aldurazyme, Naglazyme, Kuvan, and 6R-BH4 for other indications; and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: our success in the continued commercialization of Naglazyme and Kuvan; Genzyme Corporation's success in continuing the commercialization of Aldurazyme; results and timing of current and planned preclinical studies and clinical trials; our ability to successfully manufacture our products and product candidates; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products and particularly Aldurazyme, Naglazyme and Kuvan; actual sales of Aldurazyme, Naglazyme and Kuvan; Merck Serono's activities related to Kuvan; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2006 Annual Report on Form 10-K, as amended, and the factors contained in BioMarin's reports on Form 10-Q and Form 8-K. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) and Naglazyme(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Orapred(R) is a registered trademark of Medicis Pediatrics, Inc. and is used under license.

Contact:

Investors Media

Eugenia Shen Susan Berg

BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc.

(415) 506-6570 (415) 506-6594
Net Product Revenue of BioMarin Pharmaceutical Inc. and BioMarin/Genzyme LLC

For the Three Months and Years Ended December 31, 2006 and 2007

(In millions, unaudited)

Three Months Year Ended

Ended December 31, December 31,

2006 2007 2006 2007

Aldurazyme (as reported by

BioMarin/Genzyme LLC) (1) $26.5 $35.4 96.3 $123.7

Naglazyme 16.3 25.5 46.5 86.2

Kuvan -- 0.4 -- 0.4

(1) The Company recognizes its 50% share of the net income of

BioMarin/Genzyme LLC as Equity in the income of BioMarin/Genzyme LLC

in the Company's consolidated statements of operations.

BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months and Years Ended December 31, 2006 and 2007

(In thousands, except for per share data, unaudited)

Three Months Ended Year Ended

December 31, December 31,

2006 2007 2006 2007

Revenues:

Net product sales $16,310 $26,202 $49,606 $86,802

Collaborative

agreement revenues 4,882 17,506 18,740 28,264

Royalty and license

revenues 827 1,146 15,863 6,515

Total revenues 22,019 44,854 84,209 121,581

Operating expenses:

Cost of sales (1) 3,616 5,224 8,740 18,359

Research and

development (1) 20,572 24,015 66,735 78,600

Selling, general and

administrative (1) 13,719 23,891 48,507 77,539

Amortization of

acquired intangible

assets 1,093 1,093 3,651 4,371

Total operating

expenses 39,000 54,223 127,633 178,869

Loss from operations (16,981) (9,369) (43,424) (57,288)

Equity in the income

of BioMarin/Genzyme

LLC 5,670 9,366 19,274 30,525

Interest income 3,951 7,383 12,417 25,932

Interest expense (2,957) (4,080) (13,411) (14,243)

Debt conversion

expense -- -- (3,315) --

Income (loss) before

income taxes (10,317) 3,300 (28,459) (15,074)

Provision for income

taxes 74 729 74 729

Net income (loss) $(10,391) $2,571 $(28,533) $(15,803)

Net income (loss)

per share, basic $(0.11) $0.03 $(0.34) $(0.16)

Net income (loss)

per share, diluted $(0.11) $0.03 $(0.34) $(0.16)

Shares used in per

share calculation

-- basic 91,552 96,931 84,582 95,878

Shares used in per

share calculation

-- diluted 91,552 101,193 84,582 95,878

(1) The following is the stock-based compensation expense included in the

respective captions of the consolidated statements of operations

above:

Three Months Ended Year Ended

December 31, December 31,

2006 2007 2006 2007

Stock-based compensation

expense:

Cost of goods sold $-- $162 $-- $578

Research and development 1,364 2,211 4,242 6,978

Selling, general and

administrative 1,727 3,092 5,348 10,727

Total
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. BioMarin to Present at the BioCentury NewsMakers Conference
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
5. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
6. BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
7. BioMarin to Present at the Merrill Lynch 2008 Global Healthcare Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , ... December 01, 2016 , ... ... long-term client Nanowear on their recent FDA Class II 510(k) clearance for their ... significant hurdle in commercializing remote cardiac monitoring devices that rely on cloth-based nanosensors. ...
(Date:12/2/2016)... bioLytical Laboratories, a world leader in rapid infectious disease tests, introduced the Company,s newest ... members. (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , , bioLytical was invited ... introduce the INSTI HIV Self Test to 350 pharmacy representatives in Nairobi ...
(Date:11/30/2016)... Nov. 30, 2016 Biotest Pharmaceuticals Corporation (BPC), ... to announce the addition of its newest plasma collection ... Nebraska . The 15,200 square foot state-of-the-art facility ... 2016 and brings the total number of BPC,s plasma ... Carlisle , BPC,s Chief Executive Officer said "We are ...
(Date:11/30/2016)... November 2016   Merck , ein ... Unterzeichnung einer Reihe von Vereinbarungen mit Evotec ... AG Screeningleistungen für Mercks Palette genetischer Reagenzien ... auf diese Bibliotheken in Kombination mit Evotecs ... Weg zur Ermittlung und Erforschung neuer Arzneimitteltargets.    ...
Breaking Biology Technology:
(Date:11/29/2016)... CANNES, France , November 29, 2016 Nearly ... Continue Reading ... ... System is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric ...
(Date:11/21/2016)... Nov. 21, 2016   Neurotechnology , a ... technologies, today announced that the MegaMatcher On Card ... submitted for the NIST Minutiae Interoperability Exchange ... the mandatory steps of the evaluation protocol. ... continuing test of fingerprint templates used to establish ...
(Date:11/15/2016)... 2016  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... the gut microbiome, today announced the pricing of ... its common stock and warrants to purchase 50,000,000 ... to the public of $1.00 per share and ... the offering, excluding the proceeds, if any from ...
Breaking Biology News(10 mins):